N1

The firm maintains physical offices in both cities and presents the dual presence as central to its strategy. Partners split time between the two locations. The Prague office sources and supports Central European technical founders, while the San Francisco office — on Mission Street — opens access to US co-investors, follow-on capital, and customer markets for portfolio companies expanding globally.

N1 operates as a direct investor, writing first checks of $100K to $1M into pre-seed and seed-stage companies. The firm does not publicly describe a fund-of-funds allocation or LP commitment program. Its co-investment activity is structured as direct syndication alongside US venture funds rather than through fund commitments.

N1’s stated focus is AI, healthtech, and frontier tech. The firm does not publish a formal exclusion list, but its portfolio, website language, and fund descriptions contain no reference to consumer packaged goods, traditional industrials, hard commodities, or real estate. The emphasis is tightly bound to software-driven, defensible technology businesses with global scalability.

Investment decisions are made by the four named partners: Marek Moravec, Jaroslav Trojan, Klára Kocárová, and Ondřej Homola. The firm has not disclosed an investment committee structure or whether decisions require unanimous partner consent. Founder testimonials on the firm’s website suggest partners engage directly with portfolio companies through fundraising, business development, and US market entry.

N1 actively co-invests with US venture funds and highlights these relationships as a core part of its value proposition to founders. The firm’s website names 'selected co-investors' as a feature of its model and presents the San Francisco office as a bridge that enables syndication with top-tier US firms. Specific co-investor names are not publicly listed on the site.